pembrolizumab

FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
Checkpoint inhibitors flourishKey publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist
A First: Cancer Drug Is Approved on Genetic Basis, Not Tumor Location
A First: Cancer Drug Is Approved on Genetic Basis, Not Tumor LocationPembrolizumab gets FDA approval for cancers with a certain biomarker.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Uro Pipeline: FDA accepts two supplemental applications for mUC agentOther pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approvalOther pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Merck value rises after new Keytruda approvalMerck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
Immunotherapies offer promise for Hodgkin lymphomaResearchers see promising early clinical trials with checkpoint-inhibitor therapies, opening the door for checkpoint-blockade combo therapies.